Aidan P Noon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5267037/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. European Urology, 2016, 69, 300-310.	1.9	460
2	Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients. British Journal of Cancer, 2013, 108, 1534-1540.	6.4	153
3	Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy. European Urology, 2018, 73, 363-371.	1.9	139
4	Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer. JAMA - Journal of the American Medical Association, 2022, 327, 2092.	7.4	108
5	Epidemiology, aetiology and screening of bladder cancer. Translational Andrology and Urology, 2019, 8, 5-11.	1.4	97
6	p53 and MDM2 in renal cell carcinoma. Cancer, 2010, 116, 780-790.	4.1	92
7	Comparative Outcomes of Primary, Recurrent, and Progressive High-risk Non–muscle-invasive Bladder Cancer. European Urology, 2013, 63, 145-154.	1.9	68
8	Identification of Differentially Expressed Long Noncoding RNAs in Bladder Cancer. Clinical Cancer Research, 2014, 20, 5311-5321.	7.0	55
9	Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study. Journal of Clinical Oncology, 2021, 39, 202-214.	1.6	53
10	Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non–muscle-invasive Bladder Cancer: Results of a European Survey. European Urology Focus, 2019, 5, 681-688.	3.1	48
11	Long-term Outcomes from Re-resection for High-risk Non–muscle-invasive Bladder Cancer: A Potential to Rationalize Use. European Urology Focus, 2019, 5, 650-657.	3.1	38
12	Next-generation RNA Sequencing of Archival Formalin-fixed Paraffin-embedded Urothelial Bladder Cancer. European Urology, 2014, 66, 982-986.	1.9	33
13	Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. World Journal of Urology, 2017, 35, 1401-1407.	2.2	29
14	Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy. BJU International, 2012, 109, 1250-1257.	2.5	26
15	Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study. BMJ Open, 2017, 7, e017913.	1.9	25
16	Multidomain Quantitative Recovery Following Radical Cystectomy for Patients Within the Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion Versus Open Radical Cystectomy Randomised Controlled Trial: The First 30 Patients. European Urology, 2018, 74, 531-534.	1.9	24
17	Challenging current paradigms. Nature Reviews Urology, 2013, 10, 67-68.	3.8	20
18	Senescence induction in renal carcinoma cells by Nutlin-3: a potential therapeutic strategy based on MDM2 antagonism. Cancer Letters, 2014, 353, 211-219.	7.2	18

Aidan P Noon

#	Article	IF	CITATIONS
19	Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes. European Urology Focus, 2020, 6, 1226-1232.	3.1	18
20	Opportunities of next-generation sequencing in non-muscle invasive bladder cancer outcome prediction. Translational Andrology and Urology, 2017, 6, 1043-1048.	1.4	17
21	Dislocated Thompson hemiarthroplasty—the management of the recurrent dislocator. Injury, 2005, 36, 618-621.	1.7	16
22	Magnetic Resonance Imaging Characterization of a Mucinous Tubular and Spindle Cell Carcinoma of the Kidney Detected Incidentally During an Ectopic Pregnancy. Urology, 2010, 75, 247-248.	1.0	16
23	Occupation and Bladder Cancer Phenotype: Identification of Workplace Patterns That Increase the Risk of Advanced Disease Beyond Overall Incidence. European Urology Focus, 2018, 4, 725-730.	3.1	16
24	Occupational exposure to crack detection dye penetrants and the potential for bladder cancer: Table 1. Occupational and Environmental Medicine, 2012, 69, 300.2-301.	2.8	14
25	Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes. PLoS ONE, 2020, 15, e0239338.	2.5	14
26	A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 603.e1-603.e7.	1.6	13
27	Noncoding RNA in bladder cancer. Current Opinion in Urology, 2014, 24, 506-511.	1.8	12
28	All Bacillus Calmette-Guérin (BCG) Strains Are Equal, but Some BCG Strains Are More Equal Than Others. European Urology, 2014, 66, 689-691.	1.9	12
29	Selection of patients and benefit of immediate radical cystectomy for non-muscle invasive bladder cancer. Translational Andrology and Urology, 2019, 8, 101-107.	1.4	8
30	The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group. Surgical Oncology, 2020, 34, 312-317.	1.6	7
31	The Impact of Centralised Services on Metric Reflecting High-quality Performance: Outcomes from 1110 Consecutive Radical Cystectomies at a Single Centre. European Urology Focus, 2020, 7, 554-565.	3.1	7
32	Postoperative Chemotherapy Bladder Instillation After Radical Nephroureterectomy: Results of a European Survey from the Young Academic Urologist Urothelial Cancer Group. European Urology Open Science, 2020, 22, 45-50.	0.4	6
33	Impact of Anaesthetist Volume on Radical Cystectomy Outcomes. European Urology Focus, 2021, 7, 117-123.	3.1	5
34	Urothelial Bladder Cancer Urinary Biomarkers. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2014, 25, 99-114.	0.7	5
35	Re: Radical Cystectomy (Bladder Removal) Against Intravesical BCG Immunotherapy for High-risk Non-muscle Invasive Bladder Cancer (BRAVO): A Protocol for a Randomised Controlled Feasibility Study. European Urology, 2018, 73, 636.	1.9	4
36	Conditional analyses of recurrence and progression in patients with TaG1 non–muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 238.e19-238.e27.	1.6	3

Aidan P Noon

#	Article	IF	CITATIONS
37	Urinary retention and obstructive nephropathy secondary to müllerian duct cyst in an adult. Urology, 2005, 65, 587-588.	1.0	1
38	Re: The Important Role for Intravenous Iron in Perioperative Patient Blood Management in Major Abdominal Surgery: A Randomized Controlled Trial. European Urology, 2017, 71, 690-691.	1.9	1
39	Urethral recurrence after radical cystoprostatectomy: Experience from a high-volume tertiary referral centre. Journal of Clinical Urology, 2021, 14, 238-245.	0.1	1
40	Two Cases of Urethral Stricture following Insertion of Silicone Sealant into the Male Urethra. Current Urology, 2008, 2, 107-109.	0.6	0
41	Analysis of the p53 pathway in clear cell renal cell carcinoma to identify novel drug combinations Journal of Clinical Oncology, 2012, 30, 460-460.	1.6	0
42	Title is missing!. , 2020, 15, e0239338.		0
43	Title is missing!. , 2020, 15, e0239338.		0
44	Title is missing!. , 2020, 15, e0239338.		0
45	Title is missing!. , 2020, 15, e0239338.		0
46	Case of the month from the University of Sheffield, <scp>UK</scp> : Expediting definitive treatment in patients with invasive bladder cancer: an <scp>MRI</scp> â€guided pathway. BJU International, 2022, 129, 691-694.	2.5	0